OXYGEN, USP
Peakcarbon dioxide-air mixture
NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OXYGEN, USP (carbon dioxide-air mixture) is x-ray contrast activity [moa]. First approved in 2013.
Drug data last refreshed 3h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYGEN, USP is a carbon dioxide-air mixture gas administered via inhalation classified as a radiographic contrast agent. It functions through X-ray contrast activity to enhance imaging visualization. This product is used in diagnostic procedures requiring improved radiographic contrast.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), indicating stable market position but limited growth opportunities for commercial team expansion.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and peak lifecycle status, this product offers limited career growth and hiring momentum. Roles available are primarily in sustaining commercial and medical affairs functions rather than expansive team building.
Field SalesAccount Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.